%0 Journal Article
%T IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens
%A Tatsuo Miyamura
%A Tatsuo Kanda
%A Shingo Nakamoto
%A Makoto Arai
%A Masato Nakamura
%A Shuang Wu
%A Xia Jiang
%A Reina Sasaki
%A Yuki Haga
%A Shin Yasui
%A Yoshihiko Ooka
%A Tetsuhiro Chiba
%A Fumio Imazeki
%A Shigeru Mikami
%A Osamu Yokosuka
%J International Journal of Hepatology
%D 2014
%I Hindawi Publishing Corporation
%R 10.1155/2014/723868
%X Aim. Eradication of hepatitis C virus (HCV) is still challenging even if interferon- (IFN-) free regimens with direct-acting antiviral agents (DAAs) for HCV-infected individuals are available in clinical practice. IFNL4 is a newly described protein, associated with human antiviral defenses. We investigated whether IFNL4 ss469415590 variant has an effect on the prediction of treatment response in HCV-infected patients treated with IFN-including regimens. Patients and Methods. In all, 185 patients infected with HCV genotype 1 treated with peg-IFN plus ribavirin, with or without telaprevir, were genotyped for IFNL4 ss469415590. We retrospectively investigated whether the role of IFNL4 ss469415590 variant and other factors could predict sustained virological response (SVR) in Japanese patients infected with HCV genotype 1. Results. There were 65.7%, 31.5%, and 2.8% patients in the IFNL4 ss469415590 TT/TT, TT/-G, and -G/-G groups, respectively. SVR rates were 82.1% or 49.3% in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Conclusion. In the era of DAAs, measurement of IFNL4 ss469415590 variant could help the prediction of SVR in Japanese HCV genotype 1 infected individuals treated with IFN-including regimens. 1. Introduction Chronic hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC) and end-stage liver disease requiring liver transplantation in the United States [1, 2]. In Japan, HCV infection is still a major cause of HCC [3]. At present, HCV infection is a world health problem. The former standard treatment with peginterferon (peg-IFN) plus ribavirin led to ~50% and ~80% sustained virological response (SVR) rates in patients infected with HCV genotypes 1 and 2, respectively [4]. Since 2011, peg-IFN plus ribavirin with telaprevir or boceprevir has been available in the United States as well as that with telaprevir in Japan. These treatments resulted in higher SVR rates (~70% and ~80% for treatment-na£żve patients and previous treatment relapsers, resp.) in HCV genotype 1 infected patients [5]. Genome-wide association studies (GWAS) [6¨C8] revealed that several single nucleotide polymorphisms (SNPs) near the IFNL3 (previously called IL28B) coding region, such as rs8099917 and rs12978690, are associated with treatment response to peg-IFN plus ribavirin treatment.
%U http://www.hindawi.com/journals/ijh/2014/723868/